Literature DB >> 12066237

MRI of the abdomen with positive oral contrast agents for the diagnosis of inflammatory small bowel disease.

A Rieber1, K Nüssle, M Reinshagen, H-J Brambs, A Gabelmann.   

Abstract

Magnetic resonance imaging (MRI) is being used more often in the evaluation of inflammatory bowel diseases. A prerequisite for adequate image quality is the oral application of contrast medium, which can be administered with different modalities. Positive and negative oral contrast media can be used; in terms of diagnostic efficacy, there appears to be no relevant differences between them. Sequences usually are acquired using breath-hold or respiration-triggered protocols. The underlying principle is visualization of circumscribed thickening of the intestinal wall, which shows a pathologic pattern of contrast medium uptake. The available data suggest that MRI is equally as effective as enteroclysis in the primary diagnosis of Crohn's disease and actually more sensitive in the detection of extraintestinal manifestations such as fistulae or abscesses. Supporters of the method predict that MRI will replace enteroclysis in the long term.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12066237     DOI: 10.1007/s00261-001-0120-x

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  10 in total

Review 1.  Pictorial review: magnetic resonance imaging of colonic diverticulitis.

Authors:  Orla Buckley; Tony Geoghegan; Grainne McAuley; Thara Persaud; Faisal Khosa; William C Torreggiani
Journal:  Eur Radiol       Date:  2006-04-20       Impact factor: 5.315

2.  European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis.

Authors:  E F Stange; S P L Travis; S Vermeire; C Beglinger; L Kupcinkas; K Geboes; A Barakauskiene; V Villanacci; A Von Herbay; B F Warren; C Gasche; H Tilg; Stefan W Schreiber; J Schölmerich; W Reinisch
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 3.  Updating magnetic resonance imaging of small bowel: imaging protocols and clinical indications.

Authors:  Jiong Zhu; Jian-Rong Xu; Hong-Xia Gong; Yan Zhou
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

4.  Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy.

Authors:  Johannes Sailer; Philipp Peloschek; Walter Reinisch; Harald Vogelsang; Karl Turetschek; Wolfgang Schima
Journal:  Eur Radiol       Date:  2008-05-27       Impact factor: 5.315

5.  Magnetic resonance enterography in Crohn's disease: Standard and advanced techniques.

Authors:  Arda Kayhan; Jacob Oommen; Farid Dahi; Aytekin Oto
Journal:  World J Radiol       Date:  2010-04-28

6.  Bowel magnetic resonance imaging of pediatric patients with oral mannitol MRI compared to endoscopy and intestinal ultrasound.

Authors:  Arne S Borthne; Michael Abdelnoor; Jarle Rugtveit; Göri Perminow; Tor Reiseter; Nils-Einar Kløw
Journal:  Eur Radiol       Date:  2005-06-08       Impact factor: 5.315

7.  Comparison of magnetic resonance imaging colonography with conventional colonoscopy for the assessment of intestinal inflammation in patients with inflammatory bowel disease: a feasibility study.

Authors:  A G Schreyer; H C Rath; R Kikinis; M Völk; J Schölmerich; S Feuerbach; G Rogler; J Seitz; H Herfarth
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

8.  High-output fistula.

Authors:  Naila Arebi; Alastair Forbes
Journal:  Clin Colon Rectal Surg       Date:  2004-05

9.  Assessment of inflammatory activity in Crohn's disease by means of dynamic contrast-enhanced MRI.

Authors:  V A Pupillo; E Di Cesare; G Frieri; N Limbucci; M Tanga; C Masciocchi
Journal:  Radiol Med       Date:  2007-09-20       Impact factor: 3.469

10.  Value of cine MRI for better visualization of the proximal small bowel in normal individuals.

Authors:  Michael R Torkzad; Roberto Vargas; Chikako Tanaka; Lennart Blomqvist
Journal:  Eur Radiol       Date:  2007-07-28       Impact factor: 5.315

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.